Background: This study aimed to investigate the relationship between retinol-binding protein 4 (RBP4) and gestational diabetes mellitus (GDM). Methods: Seventy-six women with and without GDM were recruited. Their blood samples were collected to detect RBP4, fasting plasma glucose (FPG), fasting insulin (Fins), triglyceride (TG), total cholesterol (TC), low-density lipoprotein, high-density lipoprotein (HDL) and glycosylated hemoglobin (HbA1c) levels. Results: RBP4 (21.42 ± 3.846 vs. 39.08 ± 8.293 μg/ml), FPG, Fins, homeostasis model assessment of insulin resistance (HOMA-IR), HbA1c, and TG levels were higher, while HDL levels were lower in women with GDM (p < 0.01). In healthy controls, RBP4 concentrations were positively correlated with HOMA-IR and TG and inversely correlated with FPG and HDL (p < 0.05). Serum concentrations of RBP4 in women with GDM were inversely correlated with TC and positively correlated with maternal weight gain during pregnancy (p < 0.05). The ROC curve was drawn with a correct rate of 93.4%. Conclusions: Concentrations of serum RBP4 were significantly higher in women with GDM, suggesting that elevated RPB4 level may play a role in the pathogenesis of GDM. Meanwhile, RBP4 might be a good predictor of GDM. RBP4 is correlated with TG and HDL, indicating that RBP4 plays a role in alterations of lipid metabolism in pregnant women.

1.
Buchanan TA, Xiang A, Kjos SL, et al: What is gestational diabetes? Diabetes Care 2007;30:105-111.
2.
American Diabetes Association: Diagnosis and classification of diabetes mellitus. Diabetes Care 2010;33(suppl 1):S62-S69.
3.
Veeraswamy S, Vijayam B, Gupta VK, et al: Gestational diabetes: the public health relevance and approach. Diabetes Res Clin Pract 2012;97:350-358.
4.
Henry OA, Beischer NA: Long-term implications of gestational diabetes for the mother. Baillieres Clin Obstet Gynaecol 1991;5:461-483.
5.
Miehle K, Stepan H, Fasshauer M: Leptin, adiponectin and other adipokines in gestational diabetes mellitus and preeclampsia. Clin Endocrinol 2012;76:2-11.
6.
Klein K, Bancher-Todesca D, Leipold H, et al: Retinol-binding protein 4 in patients with gestational diabetes mellitus. J Womens Health 2010;19:517-521.
7.
Choi SH, Kwak SH, Youn BS, et al: High plasma retinol binding protein-4 and low plasma adiponectin concentrations are associated with severity of glucose intolerance in women with previous gestational diabetes mellitus. J Clin Endocrinol Metab 2008;93:3142-3148.
8.
Mazaki-Tori S, Romero R, Vaisbuch E, et al: Retinol-binding protein 4: a novel adipokine implicated in the genesis of LGA in the absence of gestational diabetes mellitus. J Perinat Med 2010;38:147-155.
9.
Butte NF: Carbohydrate and lipid metabolism in pregnancy: normal compared with gestational diabetes mellitus. Am J Clin Nutr 2000;71:1256-1261.
10.
Goldstein BJ, Scalia R: Adiponectin: a novel adipokine linking adipocytes and vascular function. J Clin Endocrinol Metab 2004;89:2563-2568.
11.
Spiegelman BM, Flier JS: Obesity and the regulation of energy balance. Cell 2001;104:531-543.
12.
Meigs JB, Panhuyen CI, Myers RH, et al: A genome-wide scan for loci linked to plasma levels of glucose and HbA(1c) in a community-based sample of Caucasian pedigrees: the Framingham Offspring Study. Diabetes 2002;51:833-840.
13.
Duggirala R, Blangero J, Almasy L, et al: Linkage of type 2 diabetes mellitus and of age at onset to a genetic location on chromosome 10q in Mexican Americans. Am J Hum Genet 1999;64:1127-1140.
14.
Quadro L, Hamberger L, Colautuoni V, et al: Understanding the physiological role of retinol-binding protein in vitamin A metabolism using transgenic and knockout mouse models. Mol Aspects Med 2003;24:421-430.
15.
Yang Q, Graham TE, Mody N, et al: Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. Nature 2005;436:356-362.
16.
Graham TE, Yang Q, Blüher M, et al: Retinol-binding protein 4 and insulin resistance in lean, obese, and diabetic subjects. N Engl J Med 2006;354:2552-2563.
17.
Cho YM, Youn BS, Lee H, et al: Plasma retinol-binding protein-4 concentrations are elevated in human subjects with impaired glucose tolerance and type 2 diabetes. Diabetes Care 2006;29:2457-2461.
18.
Balagopal P, Graham TE, Kahn BB, et al: Reduction of elevated serum retinol binding protein in obese children by lifestyle intervention: association with subclinical inflammation. J Clin Endocrinol Metab 2007;92:1971-1974.
19.
Gavi S, Stuart LM, Kelly P, et al: Retinol binding protein 4 is associated with insulin resistance and body fat distribution in non-obese subjects without type 2 diabetes. J Clin Endocrinol Metab 2007;92:1886-1890.
20.
National Diabetes Data Group: Classification and diagnosis of diabetes mellitus and other categories glucose intolerance. Diabetes 1979;28:1039-1057.
21.
Kershaw EE, Flier JS: Adipose tissue as an endocrine organ. J Clin Endorinol Metab 2004;89:2548-2556.
22.
Su YX, Hong J, Yan Q, et al: Increased serum retinol-binding protein-4 levels in pregnant women with and without gestational diabetes mellitus. Diabetes Metab 2010;36:470-475.
23.
Kim SH, Choi HJ: Retinol-binding protein 4 responses during an oral glucose tolerance testing in women with gestational diabetes mellitus. Clin Chim Acta 2007;391:123-125.
24.
Lewandowski KC, Stojanovic N, Bienkiewicz M, et al: Elevated concentrations of retinol-binding protein-4 (RBP-4) in gestational diabetes mellitus: negative correlation with soluble vascular cell adhesion molecule-1 (sVCAM-1). Gynecol Endocrinol 2008;24:300-305.
25.
Maghbooli Z, Hossein-Nezhad A, Mirzaei K, et al: Association between retinol-binding protein 4 concentrations and gestational diabetes mellitus and risk of developing metabolic syndrome after pregnancy. Reprod Sci 2010;17:196-201.
26.
Ueland T, Dalsoren T, Voldner N, et al: RBP4 is not strongly associated with insulin sensitivity in normal pregnancies. Eur J Endocrinol 2008;159:49-54.
27.
Krzyzanowska K, Zemany L, Krugluger W, et al: Serum concentrations of retinol-binding protein 4 in women with and without gestational diabetes. Diabetologia 2008;51:1115-1122.
28.
Tepper BJ, Kim YK, Shete V, et al: Serum retinol-binding protein 4 (RBP4) and retinol in a cohort of borderline obese women with and without gestational diabetes. Clin Biochem 2010;43:320-323.
29.
Jeon YE, Lee KE, Jung JA, et al: Kisspeptin, leptin, and retinol-binding protein 4 in women with polycystic ovary syndrome. Gynecol Obstet Invest 2013;75:268-274.
30.
Saucedo R, Zarate A, Basurto L, et al: Relationship between circulating adipokines and insulin resistance during pregnancy and postpartum in women with gestational diabetes. Arch Med Res 2011;42:318-323.
31.
Chan TF, Chen HS, Chen YC, et al: Increased serum retinol-binding protein 4 concentrations in women with gestational diabetes mellitus. Reprod Sci 2007;14:169-174.
32.
Lassek WD, Ganlin SJ: Changes in body fat distribution in relation to parity in American women: a covert form of maternal depletion. Am J Phys Anthropol 2006;131:295-302.
33.
Valsamakis G, Kumar S, Creatsas G, et al: The effects of adipose tissue and adipocytokines in human pregnancy. Ann NY Acad Sci 2010;1205:76-81.
34.
Özyer S, Engin-Üstün Y, Uzunlar Ö, et al: Inflammation and glycemic tolerance status in pregnancy: the role of maternal adiposity. Gynecol Obstet Invest 2014;78:53-58.
35.
Takashima N, Tomoike H, Iwai N: Retinol-binding protein 4 and insulin resistance. N Engl J Med 2006;355:1392.
36.
Lee JW, Im JA, Lee HR, et al: Visceral adiposity is associated with serum retinol binding protein-4 levels in healthy women. Obesity 2007;15:2225-2232.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.